Trials of staphylococcal protein A-treated plasma infusions in cancer therapy: clinical effects and implications for mode of action.
Contemporary topics in immunobiology, ISSN: 0093-4054, Vol: 15, Page: 239-256
1985
- 1Citations
- 3Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Book Chapter Description
The data presented here indicate that patients with advanced cancer exhibit a modest but definite objective response rate to biweekly infusions of autologous plasma treated with purified, covalently bound staphylococcal protein A in a relatively nontoxic treatment program. The possibility that responses could be enhanced by alteration of treatment parameters, improved patient selection, and/or combined therapy remains to be explored. In vitro studies indicate that tumor cell killing can be produced in an ovarian cancer cell line using ascitic fluid of some ovarian cancer patients that has been treated with small amounts of protein A covalently linked to silica gel or agarose. This may be a suitable model system for exploration of possible humoral mechanisms of protein A-associated tumoricidal effects. The available literature indicates an antitumor effect of protein A-treated patient plasma in a variety of in vitro systems, as well as in animal and human tumors in vivo. Preliminary investigations of the mechanism of these effects are inconsistent and support the view that several different mechanisms of tumor cell killing may be operative in different settings.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=0021981276&origin=inward; http://dx.doi.org/10.1007/978-1-4684-4931-0_7; http://www.ncbi.nlm.nih.gov/pubmed/3896642; http://link.springer.com/10.1007/978-1-4684-4931-0_7; https://dx.doi.org/10.1007/978-1-4684-4931-0_7; https://link.springer.com/chapter/10.1007/978-1-4684-4931-0_7; http://www.springerlink.com/index/10.1007/978-1-4684-4931-0_7; http://www.springerlink.com/index/pdf/10.1007/978-1-4684-4931-0_7
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know